Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | TTR | P02766 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18879746 | 0.83 | SMN1; SMN2 (0.38) | SMN1; SMN2GAAALDH1A1 | |
| SCHEMBL17465535 | 0.80 | SMN1; SMN2 (0.50) | SMN1; SMN2GAAALDH1A1 | |
| SCHEMBL18879744 | 0.79 | — | — | |
| SCHEMBL9735039 | 0.78 | TTR (0.43) | SMN1; SMN2TTR | |
| SCHEMBL5317147 | 0.78 | TTR (0.43) | SMN1; SMN2TTR | |
| SCHEMBL11552627 | 0.78 | TTR (0.50) | SMN1; SMN2ALDH1A1MGLLTTR | |
| SCHEMBL27017 | 0.78 | TTR (0.50) | SMN1; SMN2ALDH1A1MGLLTTR | |
| SCHEMBL31229527 | 0.78 | TTR (0.50) | SMN1; SMN2ALDH1A1MGLLTTR | |
| SCHEMBL11554965 | 0.78 | TTR (0.50) | SMN1; SMN2ALDH1A1MGLLTTR | |
| SCHEMBL25928 | 0.78 | TTR (0.50) | SMN1; SMN2ALDH1A1MGLLTTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9655982-B2 | Formation and uses of europium complexes | WAYNE STATE UNIVERSITY (US) | 2017-05-23 | — | — | US | disclosed |
| US-9655982-B2 | Formation and uses of europium complexes | WAYNE STATE UNIVERSITY (US) | 2017-05-23 | — | — | US | disclosed |
| US-20130078189-A1 | FORMATION AND USES OF EUROPIUM COMPLEXES | Wayne State Univeristy | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130078189-A1 | FORMATION AND USES OF EUROPIUM COMPLEXES | SELE, EFTUD2, SLC7A5 | SMN1; SMN2 2039/4885GAA 2922/4885ALDH1A1 4568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.